It was the third trigger of the recession indicator in less than two weeks.Bondsread more
Overstock CEO Partick Byrne has resigned from the e-commerce company after making controversial comments about his role in the "Deep State."Technologyread more
U.S. manufacturer growth slowed to the lowest level in almost 10 years in August, the latest sign that the trade war may be exacerbating the economic slowdown.Marketsread more
Automakers are trying to deal with President Trump's efforts to roll back Obama-era fuel efficiency rules.Autosread more
ARM rates are all over the place lender to lender because they are a very small percentage of new loan originations, around 6% of total mortgage application volume, according...Real Estateread more
"The president is not backing down," says CNBC's Jim Cramer, referring to Trump's repeated calls for the Fed to cut rates while talking tough on China.Economyread more
Philadelphia Fed President Patrick Harker said he doesn't see the case for additional stimulus after the Federal Reserve's July rate cut.The Fedread more
Stocks fell, giving up earlier gains as investors wondered whether the Federal Reserve will cut interest rates next month.US Marketsread more
"My sense was we've added accommodation, and it wasn't required in my view," George tells CNBC's Steve Liesman.Investingread more
Former Prudent Bear Fund manager David Tice is urging investors to brace for a massive downturn.Trading Nationread more
Samsung's Galaxy Note 10+ packs everything you need and more into a phone.Technologyread more
Johnson & Johnson got its second upgrade this week from Wall Street after Jefferies raised its rating and called the health-care company a "dividend machine."
Jefferies upgraded J&J to buy from hold on Wednesday and raised its price target, pointing to a strong, "under-modelled" pharmaceutical division that will continue to drive above-consensus revenue.
"Instead of commentators focusing on an unlikely break-up of the business, it should be appreciated for what it is — an EPS growth and dividend machine," Jefferies analyst Jeffrey Holford wrote in a note to clients. "We see multiple strong growth drivers across the Pharma business, with some of the weaker franchises also being defended by innovation."
The stock, which rose 2 percent by Wednesday afternoon after the Jefferies call, has a dividend yield of 2.5 percent. Holford believes the company will raise its payout.
Holford also raised his price target to $157 from $145, representing 17 percent upside from Tuesday's close. The stock has surged 16 percent this year.
Holford emphasized J&J's big drug sales as critical to the upgrade and saw no signs of its pharmaceutical segment slowing down. Drivers including oncology, immunology and schizophrenia medications.
"It seems very unlikely to us that the Pharma business should ever cause the overall business to decline," he said. "In 2017E we estimate that Johnsons & Johnson's Pharma division will hold 11 blockbuster products (greater than $1 billion in revenue), with 5 of these having sales of $2 billion or more."
Wells Fargo upgraded Johnson & Johnson earlier in the week, calling the third quarter a "turning point" for the stock. In that report, Wells Fargo analysts said J&J's recent acquisition of biotech company Actelion will add to the company's already-impressive drug pipeline.